Aldeyra refocuses pipeline on next-gen RASP modulators despite positive phase II success
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Basketball legend, entrepreneur, and entertainer Shaquille O’Neal partners with Lilly to encourage Americans to recognize the signs of obstructive sleep apnea and talk to their
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection conducted in June 2025
Subscribe To Our Newsletter & Stay Updated